Fellow Eye Effect with Ranibizumab for Age Related Macular Degeneration

In patients with wet Age Related Macular Degeneration, is ranibizumab intravitreal injection effective in improving visual acuity in the fellow eye?

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12607000575437

Acronym

FERMAD

Enrollment

Registered

2007-11-09

Start date

2008-02-18

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Studying the Fellow Eye Effect of ranibizumab (Lucentis) injections for macular degeneration.

Interventions

Observation post-injection by Visual Acuity (VA) measurement and Optical Coherence Tomography (OCT). Patients will be observed on 6 occassions over 3 months from their initial treatment. Visual Acuity will be tested using a standard logMAR eye chart, and retinal OCT will be performed using a Copernicus Spectral OCT scanner.

Eligibility

Sex/Gender

All

Age

50 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

• ARMD with choroidal neovascularisation in both eyes • Involvement of the foveal centre • Age 50 years or more • Visual Acuity (best corrected) of 6/12 or worse in both eyes (equivalent to >0.3 logMAR)

Exclusion criteria

• Lesion size greater than 12 optic disc areas • Previous anti Vascular Endothelial Growth Factor (anti-VEGF) therapy • Contraindication for ranibizumab treatment o Hypersensitivity to ranibizumab o Active or suspected ocular/periocular infection o Active intraocular inflammation

Outcome results